A new randomized trial of testosterone therapy with 6000 participants has started. It will run for four years and will determine the occurrence of major adverse cardiovascular events (MACE). The official title is "Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study." The trial is described on clinicaltrials.gov. This trial should definitively answer the question of TRT and cardiovascular disease.